Evidence map›Paper›PMID 34969357›Full record

ArticleBioengineered2022

miR-647 inhibits hepatocellular carcinoma cell progression by targeting protein tyrosine phosphatase receptor type F.

Xiangyang Ye, Rongxian Qiu, Xiongzhi He, Zhengting Hu, Fengfeng Zheng, Xiaogang Huang, Xuemei Xie, Feihua Chen, Hangbing Ou, Guoxian Lin

RetractedAbstract readRetracted Publication
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Xiangyang YeDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Rongxian QiuDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Xiongzhi HeDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Zhengting HuDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Fengfeng ZhengDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Xiaogang HuangDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Xuemei XieDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Feihua ChenDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Hangbing OuDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.
Guoxian LinDepartment of Infectious Diseases, Affiliated Hospital of Putian University, Putian, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a kind of malignant tumor derived from hepatocytes and hepatobiliary cells, and its occurrence is prevalent worldwide. Although medical technology is developing rapidly, the therapeutic efficacy of HCC is still poor. Emerging evidence manifests that microRNAs (miRNAs) play a crucial role in various cancers and have been regarded as cancer suppressor gene. However, the regulatory mechanisms mediated by miR-647 involved in HCC remain unclear. Hence, to clarify the regulatory mechanisms mediated by miR-647 in HCC, we studied the independent effects of miR-647 and explored protein tyrosine phosphatase receptor type F (PTPRF) in the constructed HCC cell line (HCV-huh7.5). Thereafter, we used dual-luciferase gene reporting and Western blot to investigate the relationship between PTPRF and miR-647. Furthermore, we studied the mechanism of miR-647 on PTPRF in HCV-huh7.5. We found that miR-647 could not only promote the proliferation and invasion of HCV-huh7.5 cells but also facilitate cell migration, while PTPRF has the opposite effect. Besides, the results of cell function experiment implied that the overexpression of miR-647 or inhibition of PTPFRF remarkably influenced the Erk signaling pathway, which could regulate cell proliferation, migration, and invasion. In addition, the dual luciferase reporting identified PTPRF as a direct target of miR-647. We further demonstrated that miR-647 inhibitor or PTPRF knockdown administration boosted HCV-huh7.5 cell proliferation, migration, and invasion by targeting PTPRF.These findings provided clues for the mechanism of miR-647 in promoting the biology of HCV-huh7.5 cells by inhibiting the expression level of PTPRF.

Indexed as

Carcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMAP Kinase Signaling SystemMicroRNAsReceptor-Like Protein Tyrosine Phosphatases, Class 2Up-RegulationMicroRNAsMIRN647 microRNA, humanPTPRF protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 2Erk1/2hepatocellular carcinomamiR-647PTPRF

Identifiers

PMID34969357
PMCPMC8805897

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.